Viridian Therapeutics, Inc. (VRDN) Misses Q1 EPS by 60c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q1 EPS of ($1.61), $0.60 worse than the analyst estimate of ($1.01). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $131.38 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Xylem names Andrea van der Berg as CFO, effective Sept. 2026